Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


10th World Congress on Healthcare & Technologies

Lisbon, Portugal

Marwa Ibrahim

Marwa Ibrahim

Alexandria University | Egypt

Title: A real life study on treatment of Egyptian patients with HCV genotype IV with simeprevir and sofosbuvir


Biography: Marwa Ibrahim


Treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and NS3A (non-structural protein 3A) protease inhibitor simeprevir resulted in high rates of sustained virological response in chronic hepatitis C Genotype 4.

Methods: We conducted a real life study on Egyptian patients coming to tropical medicine department clinic at El Mery main university hospital from February 2015 to February 2016 for treatment naïve and treatment experienced patients with chronic HCV genotype 4, including cirrhotics and non cirrhotics. Naïve (cirrhotics and non cirrhotics) and relapsers (non cirrhotics) received nucleotide polymerase inhibitor sofosbuvir and NS3A inhibitor simeprevir once daily for 12 weeks and 24 weeks for relapse cirrhotic patients. The primary end point was a sustained virologic response at 12 weeks after end of treatment.

Results: 30 naïve patients with HCV genotype 4 and 20 relapsers (10 non cirrhotic and 10 cirrhotic patients) were enrolled. Cirrhosis was diagnosed on ultrasound basis. Degree of fibrosis was confirmed by fibrotest in relapsers. Upon treatment of patients with sofosbuvir and semiprevir once daily for 12 weeks and 24 weeks only to cirrhotic relapsers, end of treatment PCR was negative in 100% in all groups including cirrhotics and non cirrhotics. Primary end point (SVR 12) was achieved in 100% of all patients. Second end point (SVR 24) was achieved in 96.6% of naïve patients; SVR 24 for non-cirrhotic relapsers was achieved in 100% of patients and in 90% of cirrhotic relapsers. Rash and jaundice were noticed in one patient.

Conclusions: Once daily sofosbuvir and simeprevir for 12 weeks provided high rate of sustained virological response among treatment naïve and treatment experienced patients with HCV genotype IV.

Recent Publications

[1] Mohlman, M.K., Saleh, D.A., Ezzat, S., Abdel-Hamid, M., Korba, B., Shettyia, K., et al.(2015) Viral Transmission Risk Factors in an Egyptian Population with High Hepatitis C prevalence. BMC Public Health, 15, 1030.

[2] Breban, R., Doss, W., Esmat, G., Elsayed, M., Hellard, M., Ayscue, P., et al. (2013) Towards Realistic Estimates ofHCV Incidence in Egypt. Journal of Viral Hepatitis, 20, 294-296.

[3] Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. and Raza, H. (2014) Global Epidemiology and Genotype Distribution of the Hepatitis C Virus Infection. Journal of Hepatology, 61, S45-S57.

[4] Maasoumy, B. and Wedemeyer, H. (2012) Natural History of Acute and Chronic Hepatitis. Best Practice & Research Clinical Gastroenterology, 26, 401-412.

[5] Gomez, E.V., Bertot, L.C., Rodriguez, Y.S., Gonzalez, A.T., Perez, Y.M. and Garcia, A.Y. (2014) The Natural History of HCV-Related Cirrhosis and Its Temporal Progression across the Different Clinical Stages. Hepatology International,8, 527-539.

Speaker Presentations

Speaker PPTs Click Here